Influenza virus split vaccine — Competitive Intelligence Brief

Influenza virus split vaccine (Influenza virus split vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

phase 2 vaccine Hemagglutinin (HA), Neuraminidase (NA) Infectious Disease Biologic

Target snapshot

Influenza virus split vaccine (Influenza virus split vaccine) — Jiangsu Province Centers for Disease Control and Prevention. Influenza virus split vaccines contain inactivated influenza viruses that have been disrupted to release viral antigens, which stimulate an immune response against the influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Influenza virus split vaccine TARGET	Influenza virus split vaccine	Jiangsu Province Centers for Disease Control and Prevention	phase 2	vaccine	Hemagglutinin (HA), Neuraminidase (NA)
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Vaccine Support Cp	Vaccine administration	Women and Infants Hospital of Rhode Island	marketed	vaccine	unknown
Tozinameran 6 months to 4 years of age	tozinameran-6-months-to-4-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
RSV prefusion F protein-based vaccine	rsv-prefusion-f-protein-based-vaccine	Pfizer Inc.	marketed	Viral protein subunit vaccine	Respiratory syncytial virus fusion (F) protein
15-valent pneumococcal conjugate vaccine (PCV15)	15-valent-pneumococcal-conjugate-vaccine-pcv15	Pfizer	marketed	vaccine	Streptococcus pneumoniae

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class